SE8204031L - Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effects - Google Patents
Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effectsInfo
- Publication number
- SE8204031L SE8204031L SE8204031A SE8204031A SE8204031L SE 8204031 L SE8204031 L SE 8204031L SE 8204031 A SE8204031 A SE 8204031A SE 8204031 A SE8204031 A SE 8204031A SE 8204031 L SE8204031 L SE 8204031L
- Authority
- SE
- Sweden
- Prior art keywords
- globulin
- gamma
- uropepsin
- intravenous injection
- pepsin
- Prior art date
Links
- 108010074605 gamma-Globulins Proteins 0.000 title abstract 9
- 238000010253 intravenous injection Methods 0.000 title abstract 4
- 108010079570 uropepsin Proteins 0.000 title abstract 4
- 108090000284 Pepsin A Proteins 0.000 title abstract 3
- 102000057297 Pepsin A Human genes 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 230000007935 neutral effect Effects 0.000 title abstract 2
- 229940111202 pepsin Drugs 0.000 title abstract 2
- 230000002391 anti-complement effect Effects 0.000 title 1
- 108010008730 anticomplement Proteins 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 229940088598 enzyme Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010011703 Cyanosis Diseases 0.000 abstract 1
- 108010047320 Pepsinogen A Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000027950 fever generation Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000001662 opsonic effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Prodn. of gamma-globulin, suitable for intravenous injection, comprises treating the gamma-globulin with the enzyme pepsin or uropepsin, at a pH of 6.0-7.5, pref. 6.5-7.0. Pref. both the gamma-globulin and the enzyme are of human origin. Therapeutic agents contg. a gamma-globulin and human uropepsin or uropepsinogen as stabiliser are also claimed. Pref. 0.01-5%, esp. 0.1-1%, of enzyme is used. Used for prophylactic and therapeutic treatment of bacterial and viral infections by intravenous injection of gamma-globulin. Gamma-globulin purified by known methods produces serious side-effects (sudden reduction of blood pressure, chilling, vomitting, pyrexia, cyanosis and shock) when administered intravenously. Treatment of the purified gamma-globulin by known methods (e.g. treatment with proteolytic enzymes (pepsin)) to avoid the side-effects due to complement activation give a product with a very short half-life. The present treatment, with pepin or uropepsin at neutral pH, gives a product suitable for intravenous injection, with a long circulatory half-life and with retention of the opsonic activity of the gamma globulin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8204031A SE8204031L (en) | 1982-06-29 | 1982-06-29 | Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8204031A SE8204031L (en) | 1982-06-29 | 1982-06-29 | Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8204031D0 SE8204031D0 (en) | 1982-06-29 |
| SE8204031L true SE8204031L (en) | 1983-12-30 |
Family
ID=20347231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8204031A SE8204031L (en) | 1982-06-29 | 1982-06-29 | Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effects |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE8204031L (en) |
-
1982
- 1982-06-29 SE SE8204031A patent/SE8204031L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8204031D0 (en) | 1982-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9708468A (en) | Treatment of leukocyte photopheresis. | |
| AU2544197A (en) | Photopheresis treatment of chronic hcv infections | |
| DE69834724D1 (en) | Treatment of bowel or bladder infections | |
| AU2240088A (en) | Thrombolytic agent | |
| GB1495289A (en) | Pharmaceutically active proteinaceous compounds | |
| SE8204031L (en) | Gamma-globulin mfr. for intravenous injection to treat infections - involves treatment with pepsin or uropepsin enzymes at neutral ph to reduce anti-complement side-effects | |
| IT1148197B (en) | Gamma-globulin mfr. for intravenous injection to treat infections | |
| AU4648985A (en) | Depolymerase enzymes and treatment of fireblight | |
| ES465180A1 (en) | Immunoglobulin having a reduced complement fixation, a process for its preparation and agents containing this immunoglobulin | |
| ZA814234B (en) | 1-s-alkyl-2-0-acyl-3-phosphocholine-1-mercapto-2.3-propandiols process for producing the same and pharmaceutical preparations containing the same | |
| IE44814L (en) | Treatment of gastroenteritis. | |
| EP0058015A3 (en) | Treatment of infections | |
| SU1197669A1 (en) | Method of treatment of purulent disease of the lung | |
| AU6089086A (en) | Treatment of chronic inflammatory disease | |
| GR3023046T3 (en) | Transdermal therapeutic system with pentylene tetrazol as active substance. | |
| FR2235702A1 (en) | Chymopapain from Carica papaya juice - with antiinflammatory activity for local and systemic use, e.g. in treating haematomas | |
| FR2201867A1 (en) | Chromatographic extraction of urokinase - by treating human urine extract on cellulose deae type resin | |
| FR2270847A1 (en) | Cholinomimetic/adrenomimetic compns - for treatment of the senile by increasing cerebral blood flow | |
| ARTz | Nardi. | |
| FR2155858A1 (en) | L-methylhistidine composns - for prevention and treatment of conditions due to excess histamine | |
| GB1114311A (en) | Purified 6-aminopenicillanic acid | |
| UA16000A1 (en) | Method for treatment of hypotrophy in piglings | |
| UA6061A1 (en) | Method for treating acute pneumonias complicated by abscess and protracted pneumonias | |
| FR2230340A1 (en) | Vincamine and vitamin E compsns - having synergistic activity, for treatment tt of cardiac and circulatory disorders | |
| UA31148A (en) | The method for treatment of psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAV | Patent application has lapsed |
Ref document number: 8204031-2 Effective date: 19871229 |